Navigation Links
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
Date:2/9/2009

TORONTO, Feb. 9 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, February 11, 2009 at 4:30 P.M. EST to discuss the Second Quarter fiscal 2009 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call 1(800) 771-6781 (North America), 1(212) 231-2901 (International). A replay of the conference call will be available on Transition's website www.transitiontherapeutics.com for seven days following the call.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials and potential efficacy of its products. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CDS Completes Large-Scale Transition of Medicare Data Processing
2. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
3. Is rapid transition through menopause linked to earlier onset of heart disease?
4. MEDai Presents on Transitioning Predictive Modeling Integration From Care Management to Actuarial Applications
5. Mental Health Leaders Meet with Transition Team
6. Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers
7. AUDIO from Medialink and Transitions Optical: New Years Resolutions for Healthier Eyes
8. Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers
9. SantaFe Senior Living Announces Leadership Transition
10. ConnextionsHealth Introduces Member Transition Services to Assist Health Plans in Efforts to Retain Members During Life Cycle Changes
11. Courage Center Transitional Rehabilitation Program to Participate in Learning Collaborative With Stratis Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... News Advisory/Interview Opportunity , After ... score a major victory in Europe for public health and the environment and is ... on rigorous scientific research and the overwhelming support of European citizens, the European Union ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response ... Respectful Response To Atheist Manifesto” is the creation of published author Richard Hostetter, ... for sixty years. He holds graduate degrees from Kent State University and the ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... the publication of the first issue of its companion print magazine. The new ... about cosmetic surgery thanks to information provided by board-certified doctors from across the ...
(Date:3/22/2017)... ... ... Old School Labs™, makers of the best-selling Vintage line of natural sports ... who trained with Floyd Mayweather, made his professional debut in London in 2003 and ... number of wins in contests in Britain, Germany and the U.S. , “We ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... solution provider, today announced that its digital marketing solutions have enabled Children’s Hospital ... investment in 24 months. , Recognizing the value of a digital marketing ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 2017 Serve You Rx Vermont, LLC, a wholly ... You), based in Milwaukee, Wisconsin , has ... in Middlebury, Vermont , from Pharmacy Health ... so it was perfect timing for this opportunity to present ... Serve You. "Like us, NEMOP has a high-touch service model, ...
(Date:3/22/2017)... Research and Markets has announced the addition of ... Pipeline Insight 2022" drug pipelines to their offering. ... Global ... report gives comprehensive insight on clinical and non-clinical aspects involved ... as main streamline drugs in the immunotherapy treatment. Report helps ...
(Date:3/22/2017)... Piramal Pharma Solutions (PPS), a ... special event to introduce the new and expanded manufacturing ... . The inaugural event was attended by Governor ... and Piramal Pharma Solutions CEO, Vivek Sharma ... ...
Breaking Medicine Technology: